Augmentation of peritoneal clearance by dipyridamole.
We performed a double blind crossover trial in which dipyridamole was administered to ten patients undergoing intermittent peritoneal dialysis at 2 liters/hour (10 min infusion, 30 min intraperitoneal dwell of dialysate and 20 min drainage of dialysate). After the patients received the drug for 3 days at a dose of 75 mg three times daily, peritoneal inulin clearance increased by 1.2 ml/min (P less than 0.05), and glucose absorption increased by 12.1 g (P less than 0.05). The mechanism of the observed drug-induced effects is unknown.
D000328:Adult; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007444:Inulin; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D010537:Peritoneum / Q000378:metabolism
D004176:Dipyridamole; D007444:Inulin; D005947:Glucose